M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C, Zhou X, Webb L, Yalavarthi S, Zheng W, Saha S, Schweickhardt R, Soloviev M, Jenkins MH, Brandstetter S, Belousova N, Alimzhanov M, Rabinovich B, Deshpande AM, Brewis N, Helming L.
Xu C, et al. Among authors: schweickhardt r.
Cancer Immunol Res. 2024 Feb 2;12(2):195-213. doi: 10.1158/2326-6066.CIR-23-0243.
Cancer Immunol Res. 2024.
PMID: 38091375